" class="no-js "lang="en-US"> Novo Nordisk Archives - Medtech Alert
Friday, March 31, 2023

Sort by:

Date

Top Post

NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business

NEC Corporation and NOI announced that NOI will be realigned as a subsidiary of NEC […]

Debiopharm Extends Their DNA Damage Repair Footprint With New Oncology Pipeline Entry

Debiopharm, an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer […]

Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global […]

Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo […]

Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a […]

Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines

Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery […]

Novo Nordisk to Acquire Dicerna Pharmaceuticals Including the RNAi Research Technology Platform

Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna […]

  1. Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
  2. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
  3. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
  4. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
  5. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more